Biotech Sector Review
<p>Analysts at Berenberg Bank provided a report on Biotech sector on the back of Q4 data updates, expecting the sluggish performance of smid-cap biotech sector likely to reverse in Q4 2021 and into 2022. </p>
<p>As scientific discoveries continue to drive innovation in therapeutics, the brokerage believes the fundamentals of the biotech sector remain strong; macro and sector specific factors, such as an increasing appetite from a strong investor base and the easing of the drug pricing rhetoric, provide tailwinds. Analysts at Berenberg expect IPOs, follow-on financings, and M&A activity to pick up, all of which we believe will likely attract investor interest in the sector.</p>
